Stock Movers

iHeartPodcasts

Listen for five-minute conversations on today's biggest winners and losers in the stock market.  Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

  1. HACE 1 H

    Closing Bell: Applovin, Oracle Rise; Hims & Hers Health, Workday Fall

    Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Matt Miller, Katie Greifeld, Carol Massar and Tim StenovecOn this episode of Stock Movers: - Applovin (APP) stock surged Monday after a financial publisher retracted some of its most explosive claims regarding AppLovin's alleged connections to transnational crime syndicates.Capitalwatch, a self-described independent news organization and publisher, accused AppLovin of serving as a "laundering machine" for illicit funds from Southeast Asia. It described major shareholder Hao Tang as the key facilitator of this scheme. - Oracle (ORCL) shares extended their rebound on Monday, as ramped up capex spending by US technology giants helped soothe nerves over the threat posed to the company by developments in artificial intelligence. Shares in the software bellwether rallied as much as 12%, their biggest intraday rise since Sept. 10. Even with that move — which came on the heels of Amazon.com Inc.’s pledge to spend $200 billion this year on data centers, chips and other equipment — the stock is down around 50% from its September highs. - Hims & Hers Health (HIMS) stocks fell after Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. See omnystudio.com/listener for privacy information.

    5 min
  2. HACE 2 H

    Oracle Surges; Kyndryl, Hims & Hers Health Plummet

    Today's biggest winners and losers in the stock market.On this episode of Stock Movers: - Oracle (ORCL) shares extended their rebound on Monday, as ramped up capex spending by US technology giants helped soothe nerves over the threat posed to the company by developments in artificial intelligence. Shares in the software bellwether rallied as much as 12%, their biggest intraday rise since Sept. 10. Even with that move — which came on the heels of Amazon.com Inc.’s pledge to spend $200 billion this year on data centers, chips and other equipment — the stock is down around 50% from its September highs. - Kyndryl (KD) shares plunged Monday morning after the company announced key leadership exits and a review of its accounting practices. The stock fell a record 57% before being briefly halted for volatility on news that Kyndryl Chief Financial Officer David Wyshner had left the position and that General Counsel Edward Sebold departed the post, effective immediately. On the same date, Vineet Khurana stepped down as senior vice president and global controller of the company and moved to a different role. - Hims & Hers Health (HIMS) stock plummeted Monday after Novo Nordisk filed a lawsuit, claiming the online pharmacy is "deceiving patients" with its compounded diabetes and weight-loss drugs.But it's still not clear that Novo Nordisk will ultimately win out against Hims & Hers Health, Leerink Partners analyst David Risinger said in a report. See omnystudio.com/listener for privacy information.

    5 min
  3. HACE 9 H

    Novo Says It’s Suing Hims; Lilly Strikes Deal for Biotech Orna; Alphabet Looks to Raise About $15 Billion

    Today's biggest winners and losers in the stock market.On this episode of Stock Movers:- Hims & Hers Health (HIMS) shares tumble as much as 17% in premarket trading on Monday after the telehealth company said it will stop selling its recently-launched copycat version of the new Wegovy weight-loss pill.- Eli Lilly & Co (LLY) agreed to buy closely held US biotech Orna Therapeutics Inc. for up $2.4 billion in cash, its second deal in as many days as the company expands its pipeline beyond its well-known blockbuster obesity drug Zepbound. Orna is developing a new class of treatments for certain autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. The biotech company, which is based in Watertown, Massachusetts, has struck licensing deals with other companies, including Vertex Pharmaceuticals Inc. and Merck & Co.- Alphabet (GOOG) is looking to raise about $15 billion from a US high-grade dollar bond sale, according to people with knowledge of the matter, adding to a borrowing spree by companies at the forefront of the artificial intelligence investment boom.Massive cloud-computing companies known as hyperscalers are expected to spend more than $650 billion this year to expand AI infrastructure. Since last year, the group has flooded the market with debt that investors have so far eagerly absorbed, although concerns are growing that excessive spending on AI may be fueling a bubble. See omnystudio.com/listener for privacy information.

    4 min

Acerca de

Listen for five-minute conversations on today's biggest winners and losers in the stock market.  Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

También te podría interesar